Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY2018 Earnings Presentation
15 slides from Dr. Lal Pathlabs's earnings presentation, Aug 7, 2017
Slide 1: Dr. Lal PathLabs Limited (DLPL) Q1 FY18 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY18 Results Presentation August 07, 2017
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q1 FY2018 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 189 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,759 Patient Service diagnostic services Centers (PSCs) and 5,021 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralised IT panels
Slide 4: Key Highlights
Key Highlights Volume growth is progressively picking-up and has shown QoQ improvement. During Q1 FY18 : Revenues were higher by 12% at Rs. 2,493 million driven by a combination of volumes (9% growth) and price-mix improvement (2.5%) Normalised EBITDA (after eliminating the impact of ESOP an
Slide 5: Q1 FY18 Financial Performance
Q1 FY18 Financial Performance FY'17 FY'17 Particulars (Rs. mn) Q1 FY18 Q1FY17 Growth % Ind AS IGaap Revenues 2,492.6 2,228.4 11.9% 9,123.8 9,123.8 Total Expenditure 1,837.1 1,622.9 13.2% 6,749.2 6,758.4 EBITDA 655.2 605.4 8.2% 2,374.6 2,365.4 RSU & stock based comp. cost 24.8 7.4 86.1 80.5 Normalise
Slide 6: Financial Highlights
Financial Highlights Revenues All figures in Rs mn 2,622 2,493 2,228 2,199 2,075 Q1FY17 Q2FY17 Q3FY17 Q4FY17 Q1FY18 Q1 FY18 revenues showed a continuing 11.9% YoY increase on account of volume growth of 9.1% and pricing mix benefit of 2.5%. The drivers include; • Enhanced footprint given addition
Slide 7: Financial Highlights
Financial Highlights All figures in Rs mn Normalised EBITDA excl ESOP & other Q1 FY18 normalised EBITDA (after eliminating the impact of ESOP and stock based remuneration charges other stock based remuneration charges) showed 11.0% increase on the 680 613 back of; • Progressive improvement in volu
Slide 8: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,759 5,668 1,559 4,967 5,021 189 1,340 4,225 172 164 1,064 146 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 No. of patients (mn) No. of samples (mn) 29.3 13.3 26.3 12.0 21.7 9.9 19.0 9.0 3.6 7.9 FY14 FY15 FY16
Slide 9: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “Overall, it was a productive quarter for our team in advancing our long-term strategic plans and to build a holistic diagnostics program. Our performance in Q1FY18 is largely driven b
Slide 10: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 11: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 11
Slide 12: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 12
Slide 13: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 14: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer COO (Strategic Business Unit 1) COO –
Slide 15: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests an